Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation

Pavan Bhargava, Leah Mische, Matthew D. Smith, Emily Harrington, Kathryn C. Fitzgerald, Kyle Martin, Sol Kim, Arthur Anthony Reyes, Jaime Gonzalez Cardona, Christina Volsko, Sonal Singh, Kesava Varanasi, Elias S. Sotirchos, Bardia Nourbakhsh, Ranjan Dutta, Ellen M. Mowry, Emmanuelle Waubant, Peter A. CalabresibioRxiv 2019 · DOI

TL;DR

Multiple sclerosis (MS) patients show altered bile acid metabolism with lower circulating levels of these compounds. Supplementing with the bile acid TUDCA reduced neuroinflammation and disease severity in an animal model of MS, suggesting bile acids are a promising therapeutic target.

What Problem Does This Paper Address?

Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS). While the role of the gut microbiome and its influence on MS is increasingly recognized, the specific metabolic pathways involved, particularly those related to bile acids, remain largely unexplored. Bile acids, cholesterol metabolites with signaling functions, are known to interact with immune and glial cells in the CNS. However, it was unclear if bile acid metabolism is disrupted in MS and, if so, whether this disruption contributes to the disease's neuroinflammatory processes. This paper investigates whether bile acid metabolism is altered in MS patients and explores the potential therapeutic benefits of bile acid supplementation.

Methods

The researchers employed a multi-pronged approach:

  • Metabolomic Profiling: They used both global and targeted metabolomic profiling on plasma samples from adult and pediatric MS patients and healthy controls. This allowed them to identify and quantify a wide range of bile acid metabolites.
  • In Vitro Studies: They investigated the effects of tauroursodeoxycholic acid (TUDCA), an endogenous bile acid, on isolated murine astrocytes and microglia. These cells were stimulated to mimic inflammatory conditions found in MS, and the researchers assessed how TUDCA affected their polarization (a key process in immune response and neuroinflammation).
  • Animal Model of MS: They used the experimental autoimmune encephalomyelitis (EAE) model, a standard animal model for MS, to test the therapeutic potential of TUDCA supplementation. They assessed disease severity through behavioral and pathological measures.
  • Immunohistochemistry: They examined MS brain tissue to determine the presence and location of bile acid receptors (FXR and GPBAR1) on immune and glial cells within lesions.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Bile Acids as Potential Biomarkers and Therapeutics: The study strongly suggests that altered bile acid metabolism is a hallmark of MS, not just a bystander effect. The fact that TUDCA supplementation ameliorated disease in an animal model points to bile acids as a potential therapeutic avenue.
  • Astrocytes and Microglia as Key Players: The research highlights how bile acids directly influence the behavior of astrocytes and microglia, two critical cell types in neuroinflammation. TUDCA's ability to prevent their "toxic" polarization is a significant finding.
  • Receptor-Mediated Signaling: The identification of bile acid receptors (FXR and GPBAR1) on cells within MS brain lesions provides a mechanistic link for how bile acids exert their effects in the CNS.

Key Results

  • Lower Bile Acid Levels in MS Patients: Both adult and pediatric MS patients consistently showed lower levels of various circulating bile acid metabolites compared to healthy controls. This alteration was more pronounced in progressive MS.
  • TUDCA Modulates Cell Polarization: In vitro, TUDCA significantly reduced the polarization of astrocytes to a neurotoxic (A1) phenotype and microglia to a pro-inflammatory (M1) phenotype.
  • TUDCA Ameliorates EAE: In the EAE mouse model, TUDCA treatment led to reduced disease severity, decreased demyelination, and less infiltration of immune cells and glial activation.
  • Bile Acid Receptors in MS Lesions: FXR and GPBAR1 receptors were found on immune cells, astrocytes, and vascular structures within MS brain lesions.

Limitations and Future Work

  • Cross-Sectional Design: The metabolomic analyses were cross-sectional, meaning they cannot establish causality or track changes over time in MS. Future studies should investigate how bile acid levels change throughout the disease course and how they are affected by MS-modifying therapies.
  • Limited Metabolite Measurement: The targeted cohort measured fewer bile acid metabolites than the untargeted panel, limiting direct comparisons.
  • Mechanism of Action: While TUDCA's effects are demonstrated, the precise mechanisms by which GPBAR1 activation influences astrocyte polarization require further investigation.
  • Clinical Trials: The paper highlights ongoing clinical trials of TUDCA in MS, which will be crucial for translating these findings into human therapies. Future research should also explore other bile acids and their potential roles.

Summary updated

Abstract

Abstract Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. Bile acids are cholesterol metabolites that can signal through receptors on cells throughout the body, including the CNS and immune system. Whether bile acid metabolism is abnormal in MS is unknown. Using global and targeted metabolomic profiling, we identified lower levels of circulating bile acid metabolites in multiple cohorts of adult and pediatric MS patients compared to controls. In white matter lesions from MS brain tissue, we noted the presence of bile acid receptors on immune and glial cells. To mechanistically examine the implications of lower levels of bile acids in MS, we studied the in vitro effects of an endogenous bile acid – tauroursodeoxycholic acid (TUDCA) on astrocyte and microglial polarization. TUDCA prevented neurotoxic (A1) polarization of astrocytes and pro-inflammatory polarization of microglia in a dose-dependent manner. TUDCA supplementation in experimental autoimmune encephalomyelitis reduced severity of disease, based on behavioral and pathological measures. We demonstrate that bile acid metabolism is altered in MS; bile acid supplementation prevents polarization of astrocytes and microglia to neurotoxic phenotypes and ameliorates neuropathology in an animal model of MS. These findings identify dysregulated bile acid metabolism as a potential therapeutic target in MS.
BibTeX
@misc{bhargava2019bile,
  author = {Pavan Bhargava and Leah Mische and Matthew D. Smith and Emily Harrington and Kathryn C. Fitzgerald and Kyle Martin and Sol Kim and Arthur Anthony Reyes and Jaime Gonzalez Cardona and Christina Volsko and Sonal Singh and Kesava Varanasi and Elias S. Sotirchos and Bardia Nourbakhsh and Ranjan Dutta and Ellen M. Mowry and Emmanuelle Waubant and Peter A. Calabresi},
  title = {{Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation}},
  year = {2019},
  doi = {10.1101/627356},
  howpublished = {bioRxiv},
}
Figure